135 related articles for article (PubMed ID: 30660120)
1. Overall survival and response to radiation and targeted therapies among patients with renal cell carcinoma brain metastases.
Juloori A; Miller JA; Parsai S; Kotecha R; Ahluwalia MS; Mohammadi AM; Murphy ES; Suh JH; Barnett GH; Yu JS; Vogelbaum MA; Rini B; Garcia J; Stevens GH; Angelov L; Chao ST
J Neurosurg; 2019 Jan; 132(1):188-196. PubMed ID: 30660120
[TBL] [Abstract][Full Text] [Related]
2. Melanoma brain metastasis: the impact of stereotactic radiosurgery, BRAF mutational status, and targeted and/or immune-based therapies on treatment outcome.
Kotecha R; Miller JA; Venur VA; Mohammadi AM; Chao ST; Suh JH; Barnett GH; Murphy ES; Funchain P; Yu JS; Vogelbaum MA; Angelov L; Ahluwalia MS
J Neurosurg; 2018 Jul; 129(1):50-59. PubMed ID: 28799876
[TBL] [Abstract][Full Text] [Related]
3. Improving the Prognostic Value of Disease-Specific Graded Prognostic Assessment Model for Renal Cell Carcinoma by Incorporation of Cumulative Intracranial Tumor Volume.
Ali MA; Hirshman BR; Wilson B; Schupper AJ; Joshi R; Proudfoot JA; Goetsch SJ; Alksne JF; Ott K; Aiyama H; Nagano O; Carter BS; Chiang V; Serizawa T; Yamamoto M; Chen CC
World Neurosurg; 2017 Dec; 108():151-156. PubMed ID: 28754641
[TBL] [Abstract][Full Text] [Related]
4. Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma.
Miller JA; Balagamwala EH; Angelov L; Suh JH; Rini B; Garcia JA; Ahluwalia M; Chao ST
J Neurosurg Spine; 2016 Dec; 25(6):766-774. PubMed ID: 27391397
[TBL] [Abstract][Full Text] [Related]
5. Overall survival and the response to radiotherapy among molecular subtypes of breast cancer brain metastases treated with targeted therapies.
Miller JA; Kotecha R; Ahluwalia MS; Mohammadi AM; Chao ST; Barnett GH; Murphy ES; Vogelbaum MA; Angelov L; Peereboom DM; Suh JH
Cancer; 2017 Jun; 123(12):2283-2293. PubMed ID: 28192598
[TBL] [Abstract][Full Text] [Related]
6. Metastatic renal cell carcinoma to the brain: optimizing patient selection for gamma knife radiosurgery.
Stenman M; Benmakhlouf H; Wersäll P; Johnstone P; Hatiboglu MA; Mayer-da-Silva J; Harmenberg U; Lindskog M; Sinclair G
Acta Neurochir (Wien); 2021 Feb; 163(2):333-342. PubMed ID: 32902689
[TBL] [Abstract][Full Text] [Related]
7. Predictors of quality of life and survival following Gamma Knife surgery for lung cancer brain metastases: a prospective study.
Bragstad S; Flatebø M; Natvig GK; Eide GE; Skeie GO; Behbahani M; Pedersen PH; Enger PØ; Skeie BS
J Neurosurg; 2018 Jul; 129(1):71-83. PubMed ID: 28820304
[TBL] [Abstract][Full Text] [Related]
8. Impact of 2-staged stereotactic radiosurgery for treatment of brain metastases ≥ 2 cm.
Angelov L; Mohammadi AM; Bennett EE; Abbassy M; Elson P; Chao ST; Montgomery JS; Habboub G; Vogelbaum MA; Suh JH; Murphy ES; Ahluwalia MS; Nagel SJ; Barnett GH
J Neurosurg; 2018 Aug; 129(2):366-382. PubMed ID: 28937324
[TBL] [Abstract][Full Text] [Related]
9. Impacts of EGFR-mutation status and EGFR-TKI on the efficacy of stereotactic radiosurgery for brain metastases from non-small cell lung adenocarcinoma: A retrospective analysis of 133 consecutive patients.
Yomo S; Oda K
Lung Cancer; 2018 May; 119():120-126. PubMed ID: 29656746
[TBL] [Abstract][Full Text] [Related]
10. Impact of Tyrosine Kinase Inhibitors (TKIs) Combined With Radiation Therapy for the Management of Brain Metastases From Renal Cell Carcinoma.
Khan M; Zhao Z; Arooj S; Liao G
Front Oncol; 2020; 10():1246. PubMed ID: 32793497
[No Abstract] [Full Text] [Related]
11. Factors affecting survival in 37 consecutive patients undergoing de novo stereotactic radiosurgery for contiguous sites of vertebral body metastasis from renal cell carcinoma.
Sellin JN; Reichardt W; Bishop AJ; Suki D; Rhines LD; Settle SH; Brown PD; Li J; Rao G; Chang EL; Tatsui CE
J Neurosurg Spine; 2015 Jan; 22(1):52-9. PubMed ID: 25360530
[TBL] [Abstract][Full Text] [Related]
12. Imaging-defined necrosis after treatment with single-fraction stereotactic radiosurgery and immune checkpoint inhibitors and its potential association with improved outcomes in patients with brain metastases: an international multicenter study of 697 patients.
Lehrer EJ; Ahluwalia MS; Gurewitz J; Bernstein K; Kondziolka D; Niranjan A; Wei Z; Lunsford LD; Fakhoury KR; Rusthoven CG; Mathieu D; Trudel C; Malouff TD; Ruiz-Garcia H; Bonney P; Hwang L; Yu C; Zada G; Patel S; Deibert CP; Picozzi P; Franzini A; Attuati L; Prasad RN; Raval RR; Palmer JD; Lee CC; Yang HC; Jones BM; Green S; Sheehan JP; Trifiletti DM
J Neurosurg; 2023 May; 138(5):1178-1187. PubMed ID: 36115055
[TBL] [Abstract][Full Text] [Related]
13. Is upfront stereotactic radiosurgery a rational treatment option for very elderly patients with brain metastases? A retrospective analysis of 106 consecutive patients age 80 years and older.
Yomo S; Hayashi M
BMC Cancer; 2016 Dec; 16(1):948. PubMed ID: 27978813
[TBL] [Abstract][Full Text] [Related]
14. The risk of radiation necrosis following stereotactic radiosurgery with concurrent systemic therapies.
Kim JM; Miller JA; Kotecha R; Xiao R; Juloori A; Ward MC; Ahluwalia MS; Mohammadi AM; Peereboom DM; Murphy ES; Suh JH; Barnett GH; Vogelbaum MA; Angelov L; Stevens GH; Chao ST
J Neurooncol; 2017 Jun; 133(2):357-368. PubMed ID: 28434110
[TBL] [Abstract][Full Text] [Related]
15. Combined stereotactic radiosurgery and tyrosine kinase inhibitor therapy versus tyrosine kinase inhibitor therapy alone for the treatment of non-small cell lung cancer patients with brain metastases.
Chiou GY; Chiang CL; Yang HC; Shen CI; Wu HM; Chen YW; Chen CJ; Luo YH; Hu YS; Lin CJ; Chung WY; Shiau CY; Guo WY; Pan DH; Lee CC
J Neurosurg; 2022 Aug; 137(2):563-570. PubMed ID: 34920439
[TBL] [Abstract][Full Text] [Related]
16. Stereotactic Radiosurgery for Women Older than 65 with Breast Cancer Brain Metastases.
Upadhyay R; Klamer BG; Perlow HK; White JR; Bazan JG; Jhawar SR; Blakaj DM; Grecula JC; Arnett A; Mestres-Villanueva MA; Healy EH; Thomas EM; Chakravarti A; Raval RR; Lustberg M; Williams NO; Palmer JD; Beyer SJ
Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201564
[TBL] [Abstract][Full Text] [Related]
17. The impact of tyrosine kinase inhibitors on the multimodality treatment of brain metastases from renal cell carcinoma.
Verma J; Jonasch E; Allen PK; Weinberg JS; Tannir N; Chang EL; Mahajan A
Am J Clin Oncol; 2013 Dec; 36(6):620-4. PubMed ID: 22892430
[TBL] [Abstract][Full Text] [Related]
18. Repeat stereotactic radiosurgery as salvage therapy for locally recurrent brain metastases previously treated with radiosurgery.
McKay WH; McTyre ER; Okoukoni C; Alphonse-Sullivan NK; Ruiz J; Munley MT; Qasem S; Lo HW; Xing F; Laxton AW; Tatter SB; Watabe K; Chan MD
J Neurosurg; 2017 Jul; 127(1):148-156. PubMed ID: 27494815
[TBL] [Abstract][Full Text] [Related]
19. BRAF V600E mutation and BRAF kinase inhibitors in conjunction with stereotactic radiosurgery for intracranial melanoma metastases.
Xu Z; Lee CC; Ramesh A; Mueller AC; Schlesinger D; Cohen-Inbar O; Shih HH; Sheehan JP
J Neurosurg; 2017 Mar; 126(3):726-734. PubMed ID: 27203149
[TBL] [Abstract][Full Text] [Related]
20. Stereotactic radiosurgery with concurrent lapatinib is associated with improved local control for HER2-positive breast cancer brain metastases.
Parsai S; Miller JA; Juloori A; Chao ST; Kotecha R; Mohammadi AM; Ahluwalia MS; Murphy ES; Barnett GH; Vogelbaum MA; Angelov L; Peereboom DM; Suh JH
J Neurosurg; 2019 Feb; 132(2):503-511. PubMed ID: 30738402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
